

Understanding NICE guidance


Information for people who use NHS services

Rivaroxaban to reduce the risk of venous thromboembolism after hip or knee replacement surgery

NICE 'technology appraisal guidance' advises on when and how drugs and other treatments should be used in the NHS.

This leaflet is about when **rivaroxaban** should be used to reduce the risk of thromboembolism in adults who have surgery to replace their hip or knee joints in the NHS in England and Wales. It explains guidance (advice) from NICE (the National Institute for Health and Clinical Excellence). It does not cover using rivaroxaban to reduce the risk of venous thromboembolism in adults who have had other types of surgery. It is written for people who are having or have had an operation to replace their hip or knee joints but it may also be useful for their families or carers or anyone with an interest in the topic.

It does not describe venous thromoboembolism or the treatments in detail – a member of your healthcare team should discuss these with you. You can get more information from the organisations listed on the back page.



This may not be the only possible treatment for preventing venous thromboembolism. Your healthcare team should talk to you about whether it is suitable for you and about other treatment options available.

What has NICE said?

Rivaroxaban is recommended as a possible treatment to reduce the risk of venous thromboembolism in adults who have surgery to replace their hip or knee.

Venous thromboembolism

When a blood clot forms in one of the deep veins in the leg, thigh, pelvis or arm it is known as deep vein thrombosis. The clot itself is not life threatening, but if it comes loose it can be carried in the blood to another part of the body where it can cause problems – this is called venous thromboembolism.

If the clot travels to the lungs it is called a pulmonary embolism and it can be fatal. Even if a blood clot does not come loose, it can still cause long-term damage to the veins leading to pain and swelling.

People having surgery to replace their hip or knee joint are at risk of venous thromboembolism because they are inactive during and after their operation and because of damage caused during surgery.

Rivaroxaban

Rivaroxaban (also known as Xarelto) is a drug that helps to prevent blood from clotting. It does this by stopping a substance called Factor Xa from working. Factor Xa is necessary in the formation of blood clots. Rivaroxaban should be given shortly after surgery and for a few weeks after this to help prevent venous thromboembolism.

What does this mean for me?

When NICE recommends a treatment, the NHS must make sure it is available to those people it could help, normally within 3 months of the guidance being issued. So, if you are having surgery to replace your hip or knee joint, and your doctor thinks that rivaroxaban is the right treatment for you, you should be able to have the treatment on the NHS. Please see www.nice.org.uk/aboutguidance if the treatment is not available.

More information

The organisations below can provide more information and support for people having hip or knee replacement surgery. NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

- Anticoagulation Europe, 020 8289 6875 www.anticoagulationeurope.org
- Lifeblood: The Thrombosis Charity, 020 7633 9937 www.thrombosis-charity.org.uk

NHS Choices (www.nhs.uk) may be a good place to find out more. Your local patient advice and liaison service (usually known as 'PALS') may also be able to give you more information and support.

About NICE

NICE produces guidance (advice) for the NHS about preventing, diagnosing and treating medical conditions. The guidance is written by independent experts, including healthcare professionals and people representing patients and carers. They consider the evidence on the disease and treatments, the views of patients and carers and the experiences of doctors, and consider the costs involved. Staff working in the NHS are expected to follow this guidance.

To find out more about NICE, its work and how it reaches decisions, see www.nice.org.uk/aboutquidance

This leaflet and other versions of the guidance aimed at healthcare professionals are available at www.nice.org.uk/TA170

You can order printed copies of this leaflet from NICE publications (phone 0845 003 7783 or email publications@nice.org.uk and quote reference N1855). The NICE website has a screen reader service called Browsealoud, which allows you to listen to our guidance. Click on the Browsealoud logo on the NICE website to use this service.

We encourage NHS and voluntary organisations to use text from this leaflet in their own information about reducing the risk of venous thromboembolism after hip or knee replacement surgery in adults.